Help | RSS Feed

Rexahn Pharmaceuticals, Inc. (NASD:REXN) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Rexahn Pharmaceuticals, Inc. (NASD:REXN) seasonal charts above shows that a Buy Date of December 28 and a Sell Date of May 24 has resulted in a geometric average return of 40.88% above the benchmark rate of the S&P 500 Total Return Index over the past 15 years. This seasonal timeframe has shown positive results compared to the benchmark in 11 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 15 years by an average of 60.29% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Rexahn Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is dedicated to the discovery, development, and commercialization of treatments for cancer. Its mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn has developed three clinical-stage drug candidates: RX-3117, Supinoxin (RX-5902) and Archexin. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action.

To download REXN seasonal chart data, please log in or Subscribe.


Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Sponsored By...
Seasonal Advantage Portfolio by CastleMoore